New U.S. patent issued covering the identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO 2 )) prognostic for potential opaganib efficacy in treating COVID-19, valid through 204 Published post-hoc data from opaganib's Phase2/3 study showed that patients with ≤60% FiO 2 levels had better outcomes after 14 days' opaganib treatment (n=117) compared to placebo (n=134), including: increased number of patients no longer requiring supplemental oxygen by day 14 of opaganib treatment (76.
9% vs. 63.4%; p-value =0.
033), a 62.6% reduction in intubation/mechanical ventilation (6.84% vs.
17.91%; p-value=0.012) and a clinically meaningful 62% reduction in mortality (5.
98% vs. 16.7%; p-value=0.
019) by day 42 [ 1] With multiple U.S. government collaborations for medical countermeasure and pandemic preparedness, opaganib is a novel, host-directed, potentially broad acting, orally administered small molecule drug with demonstrated safety & efficacy profiles, being developed for various oncology, viral infection s, inflammatory diseases and nuclear/radioprotection indications TEL-AVIV, Israel and RALEIGH, N.
C. , Sept. 30, 2024 /PRNewswire/ -- RedHill Biopharma Ltd.
(Nasdaq: RDHL ) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new U.S. patent for identification of a novel biomarker of coronavirus pneumonia (≤60% fraction of inspired oxygen (FiO 2 )) prognostic for potential opaganib [2] effic.